While the BEECH trial shows that combination of the ATP-competitive pan-Akt inhibitor capivasertib with paclitaxel, compared to paclitaxel monotherapy, has no significant improvement in the median progression-free survival of patients with advanced or metastatic ER+/HER2−/PIK3CA-mutant breast cancer [218], the FAKTION trial demonstrates that combined treatment of aromatase inhibitor-resistant, advanced or metastatic ER+/HER2− breast cancer with capivasertib and fulvestrant significantly increased the progression-free survival [219]. Here, AKT1 is linked to breast carcinoma.